EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer

Carly C Barron iD, Thais Baccili Cury Megid, Yangqing Deng, Vijithan Sugumar, Sara Ladak, Aruz Mesci, Michael Yan, Jelena Lukovic, Monika K Krzyzanowska, Anna M Sawka, Ozgur Mete iD, Lucy X Ma iD

The Oncologist · 06.06.2026 · 31 (7)

DOI: 10.1093/oncolo/oyag211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 29.05.2026. Verfasst von Carly C Barron und 11 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Oncology Site Group, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. Hauptthemen laut MEDLINE: Brain Neoplasms, Thyroid Neoplasms. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brain metastases in advanced thyroid cancer may be underrecognized due to lack of routine brain imaging. We characterized the clinical and molecular features, risk factors, and survival outcomes of patients with non-anaplastic follicular cell-derived thyroid carcinoma (FCDTC) with brain metastases.

Methods

This retrospective cohort study included patients with advanced non-anaplastic FCDTC treated in the Medical Oncology Department at Princess Margaret Cancer Centre between 2007 and 2022. Clinicopathologic and treatment data were extracted from electronic records, and all tumors underwent targeted next-generation sequencing. Risk factors for brain metastasis were assessed using logistic regression, and overall survival was analyzed with Kaplan-Meier and Cox proportional hazards models.

Results

Of 187 patients with advanced non-anaplastic FCDTC, 32 (17%) were diagnosed with brain metastases. Dedicated brain imaging was performed in 56% of patients, and most metastases (78%) were asymptomatic and incidentally detected. Lung metastases were associated with higher risk of developing brain metastases (aOR 8.27, 95% CI 1.87-36.46). ARID2 mutations were enriched in patients with brain metastases (9% vs 1%, P = .02). Survival did not differ between patients with and without brain metastases. Patients with brain metastases who had an ECOG performance status ≥2 (aHR 6.30, 95% CI 1.61-24.64) or ≥4 brain metastases (aHR 4.92, 95% CI 1.45-16.64) had worse survival. Molecular alterations were not predictive of survival.

Conclusion

Brain metastases occurred more frequently than previously reported. Lung metastases were associated with higher risk of developing brain metastases, and performance status and lesion number were associated with survival. These findings support consideration of brain metastasis screening in advanced thyroid cancer and may inform future prognostic and treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsThyroid NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultPrognosisAgedRisk FactorsMutation

Stichwörter der Autor:innen

brain neoplasmsmutationprognosisretrospective studythyroid neoplasms

Autor:innen und Institutionen

  • Endocrine Oncology Site Group, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
  • Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
  • Dr. Léon-Richard Oncology Centre, Vitalité Health Network, Moncton, NB E1C 8X3, Canada.
  • Department of Biostatistics, University Health Network, Toronto, ON M5G 1X6, Canada.
  • Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada.

ORCID-Profile: Carly C Barron, Ozgur Mete, Lucy X Ma

Zitieren

APA

Barron, C. C., Megid, T. B. C., Deng, Y., Sugumar, V., Ladak, S., Mesci, A., Yan, M., Lukovic, J., Krzyzanowska, M. K., Sawka, A. M., Mete, O., & Ma, L. X. (2026). Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag211

Vancouver

Barron CC, Megid TBC, Deng Y, Sugumar V, Ladak S, Mesci A, et al. Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag211

BibTeX
@article{Barron2026,
  author = {Barron, Carly C and Megid, Thais Baccili Cury and Deng, Yangqing and Sugumar, Vijithan and Ladak, Sara and Mesci, Aruz and Yan, Michael and Lukovic, Jelena and Krzyzanowska, Monika K and Sawka, Anna M and Mete, Ozgur and Ma, Lucy X},
  title = {Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {7},
  doi = {10.1093/oncolo/oyag211}
}
Kostenlos starten →